Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies

References

• Chobanian AV, Bakris GL, Black HR. et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-521Chobanian AV, Bakris GL, Black HR. et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97.2ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97.
   Google Scholar
• Sharma AM, Engeli S. Managing big issues on lean evidence: treating obesity hypertension. Nephrol Dial Transplant 2002; 17:353–53Sharma AM, Engeli S. Managing big issues on lean evidence: treating obesity hypertension. Nephrol Dial Transplant 2002; 17:353–5
   PubMed Web of Science ®Google Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443–624Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443–62
   PubMed Web of Science ®Google Scholar
• Weber MA. Creating a combination antihypertensive regimen: what does the research show? J Cin Hypertens (Greenwich) 2003;5(Suppl 3)::12–205Weber MA. Creating a combination antihypertensive regimen: what does the research show? J Cin Hypertens (Greenwich) 2003;5(Suppl 3)::12–20
   PubMedGoogle Scholar
• Mallion J-M, Carretta R, Trenkwalder P. et al. on behalf of the Co-Diovan Study Group. Valsartan/hydrocholorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003;12(Suppl 1):36-436Mallion J-M, Carretta R, Trenkwalder P. et al. on behalf of the Co-Diovan Study Group. Valsartan/hydrocholorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003;12(Suppl 1):36-43
   Google Scholar
• Lacourcière Y, Poirier L, Hebert D. et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27:1013–217Lacourcière Y, Poirier L, Hebert D. et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27:1013–21
   PubMed Web of Science ®Google Scholar
• Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics: advantages of combination. Blood Press 2005;14:6–118Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics: advantages of combination. Blood Press 2005;14:6–11
   PubMed Web of Science ®Google Scholar
• Palatini P. Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich) 2005;7:96–1019Palatini P. Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich) 2005;7:96–101
   PubMedGoogle Scholar
• Benz JR, Black HR, Graff A. et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–6610Benz JR, Black HR, Graff A. et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–66
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S. et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219–2411Zillich AJ, Garg J, Basu S. et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219–24
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Weinberger M. et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61–7312Pool JL, Glazer R, Weinberger M. et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61–73
   PubMed Web of Science ®Google Scholar
• Harrell FE. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer, 200113Harrell FE. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2001
   Google Scholar
• Faraway JJ. On the cost of data analysis. J Computational and Graphical Statistics 1992;1:213–2914Faraway JJ. On the cost of data analysis. J Computational and Graphical Statistics 1992;1:213–29
   Google Scholar
• Moyé LA. Statistical reasoning in medicine: the intuitive p value primer. New York: Springer, 200015Moyé LA. Statistical reasoning in medicine: the intuitive p value primer. New York: Springer, 2000
   Google Scholar
• Poole C. Beyond the confidence interval. Am J Public Health 1987;77:195–9916Poole C. Beyond the confidence interval. Am J Public Health 1987;77:195–99
   PubMed Web of Science ®Google Scholar
• Gardner MJ, Altman DG. Confidence intervals rather than p values: estimation rather than hypothesis testing. BMJ 1986; 292:746–5017Gardner MJ, Altman DG. Confidence intervals rather than p values: estimation rather than hypothesis testing. BMJ 1986; 292:746–50
   PubMed Web of Science ®Google Scholar
• Lang JM, Rothman KJ, Cann CI. That confounded p-value. Epidemiology 1998;9:7–818Lang JM, Rothman KJ, Cann CI. That confounded p-value. Epidemiology 1998;9:7–8
   PubMed Web of Science ®Google Scholar
• Van Belle G. Statistical rules of thumb. Wiley series in probability and statistics. New York: John Wiley & Sons, 200219Van Belle G. Statistical rules of thumb. Wiley series in probability and statistics. New York: John Wiley & Sons, 2002
   Google Scholar
• Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006;20:169–7520Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006;20:169–75
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens 2004;22:847-5721Staessen JA, Thijs L, Fagard R. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens 2004;22:847-57
   Google Scholar
• Caro JJ, Salas M, Speckman JL. et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160:31–722Caro JJ, Salas M, Speckman JL. et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160:31–7
   PubMed Web of Science ®Google Scholar
• Caro JJ, Speckman JL, Salas M. et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41–623Caro JJ, Speckman JL, Salas M. et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41–6
   PubMed Web of Science ®Google Scholar
• Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2:515–2424Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2:515–24
   PubMedGoogle Scholar